Bone Sarcomas

  • T. D. Peabody
  • C. W. Ryan


Sarcomas of bone are a rare group of malignant tumors with an incidence of approximately 2000 per year in the United States [1]. Protean manifestations and their rarity often present diagnostic and therapeutic challenges to the physicians caring for these patients. Often, the disease and treatment compromise limb function, resulting in disability. More importantly though, most patients with highgrade sarcomas of bone develop metastatic disease and without effective systemic and local therapy will not survive. Recent advances in medical oncology and limb salvage operative techniques have had significant positive effects on the lives of these patients.


Clin Oncol Limb Salvage Primitive Neuroectodermal Tumor Bone Sarcoma Metastatic Osteogenic Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics 2001. CA Cancer J Clin 2001:15–36CrossRefGoogle Scholar
  2. 2.
    Mirra JM (1989) Bone tumors. Clinical, radiographic, and pathologic correlation. Lea and Febiger, PhiladelphiaGoogle Scholar
  3. 3.
    Weis L (1998) Common malignant bone tumors. In: Simon MA, Springfield DS (eds) Surgery for bone and soft-tissue tumors. Lippincott-Raven, Philadelphia, pp 265–298Google Scholar
  4. 4.
    Goorin AM, Abelson HT, Frei E (1985) Osteosarcoma: fifteen years later. N Engl J Med 313:1637–1643PubMedCrossRefGoogle Scholar
  5. 5.
    Li FP, Froumeni JF (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 71:747–752PubMedGoogle Scholar
  6. 6.
    Wold LE, McLeod RA, Sirn FH, Unni KK (1990) Atlas of orthopaedic pathology. Saunders, PhiladelphiaGoogle Scholar
  7. 7.
    Demay CT (1996) Gene rearrangements in Ewing’s sarcoma. Cancer Invest 14:83–88CrossRefGoogle Scholar
  8. 8.
    American Joint Committee on Cancer (1997) Bone. In: Beahrs OH, Myers MH (eds) Manual for staging, 5th edn. Lippincott, Philadelphia, pp 143–147Google Scholar
  9. 9.
    Mankin HJ, Mankin CJ, Simon MA (1997) The hazards of biopsy, revisited. J Bone Joint Surg 78:656–663Google Scholar
  10. 10.
    Enneking WF, Spanier SS, Goodman MA (1990) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 153:106–120Google Scholar
  11. 11.
    Friedman M, Carter S (1972) The therapy osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4:487–510CrossRefGoogle Scholar
  12. 12.
    Jaffe N, Paed D (1972) Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30:1627-153:1Google Scholar
  13. 13.
    Cortes EP, Holland IF, Wang JJ et al (1974) Amputation and Adriamycin in primary osteosarcoma. N Engl Med 291: 998–1000CrossRefGoogle Scholar
  14. 14.
    Jaffe N, Frei F, Traggis D et al (1974) Adjuvant methotrexate and citrovorum factor treatment of osteogenic sarcoma. N Engl J Med 291:994–997PubMedCrossRefGoogle Scholar
  15. 15.
    Suttow W, Sullivan M, Fernbach D et al (1975) Multi-drug chemotherapy in primary treatment of osteogenic sarcoma. Cancer 36:1598–1602CrossRefGoogle Scholar
  16. 16.
    Taylor W, Ivins J, Dahlin D et al (1978) Osteogenic sarcoma experience of the Mayo Clinic 1963–1974. In: Windhort T (ed) Immunotherapy of cancer: present status of trials in man, vol 6. Raven, New York, pp 257–269Google Scholar
  17. 17.
    Edmonson JH, Green SJ, Ilvins JC et al (1984) A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment of primary osteosarcoma. J Clin Oncol 2: 152–156PubMedGoogle Scholar
  18. 18.
    Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy of relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600–1606PubMedCrossRefGoogle Scholar
  19. 19.
    Eilber FR, Guiliano AE, Eckardt J et al (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21–26PubMedGoogle Scholar
  20. 20.
    Cortes EP, Holland JF, Wang JJ et al (1972) Doxorubicin in disseminated osteosarcoma. JAMA 221:1132–1138CrossRefGoogle Scholar
  21. 21.
    Ochs JJ, Freeman AI, Douglass HO et al (1978) cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62:239–245PubMedGoogle Scholar
  22. 22.
    Marti C, Kroner T, Remagen W et al (1985) High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 69: 1132–1138Google Scholar
  23. 23.
    Pratt CB, Horowitz ME, Meyer WH et al (1987) Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 62:239–245Google Scholar
  24. 24.
    Voute PA, Souhami RL, Nooij M et al (1999) A phase II study of cisplatin, ifosfamide and doxorubicin in operable, primary, axial skeletal, and metastatic osteosarcoma. Ann Oncol 10:1211–1218PubMedCrossRefGoogle Scholar
  25. 25.
    Winkler K, Beron G, Delling G et al (1988) Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337PubMedGoogle Scholar
  26. 26.
    Jaffe N, Knapp J, Chuang VP et al (1983) Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Cancer 51:402–407PubMedCrossRefGoogle Scholar
  27. 27.
    Bacci G, Ruggier P, Picci P et al (1996) Intraarterial versus intravenous cisplatinum in addition to systemic and high dose Adriamycin and high dose methotrexate in the neoadjuvant treatment of osteosarcoma of the extremities. Results of a randomized trial study. J Chemother 9:70–81Google Scholar
  28. 28.
    Souhami RL, Craft AW, Van der Eijken JW et al (1997) Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350:911–917PubMedCrossRefGoogle Scholar
  29. 29.
    Rosen G, Caparros B, Huvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221–1230PubMedCrossRefGoogle Scholar
  30. 30.
    Jaffe N, Watts H, Frei E et al (1977) Limb-preservation in osteogenic sarcoma: a preliminary report and recent results. Cancer Res 62:114–122Google Scholar
  31. 31.
    Rosen G, Marcove R, Caparros B et al (1977) Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163–2177CrossRefGoogle Scholar
  32. 32.
    Benjamin RS, Patel SR, Armen T et al (1995) The value of ifosfamide in postoperative neoadjuvant chemotherapy of osteosarcoma (abstract no. 190). Proc Am Soc Clin Oncol 14:516AGoogle Scholar
  33. 33.
    Provisor AJ, Ettinger LJ, Nachman JB et al (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84PubMedGoogle Scholar
  34. 34.
    Bacci G, Ferrari S, Bertoni F et al (2000) Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Institute Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. J Clin Oncol 18:4016–4027PubMedGoogle Scholar
  35. 35.
    Rosen G, Huvos AG, Mosende C et al (1978) Chemotherapy and thoracotomy for metastatic osteogenic sarcoma. A model for adjuvant chemotherapy and the rationale for the timing of thoracic surgery. Cancer 41:841–849PubMedCrossRefGoogle Scholar
  36. 36.
    De Alava E, Gerald WL (2000) Molecular biology of the Ewing’s sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 18:204–213PubMedGoogle Scholar
  37. 37.
    Nesbit ME Jr, Gehan EA, Burgert EO Jr et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 9:1664–1674Google Scholar
  38. 38.
    Rosito P, Mancini AF, Rondelli R et al (1999) Italian cooperative study for the treatment of children and young adults with localized Ewing sarcoma of bone. Cancer 86:421–428PubMedCrossRefGoogle Scholar
  39. 39.
    Grier HE, Krailo M, Link M et al (1994) Improved outcome in non-metastatic Ewing’s sarcoma (EWS) and PNET of bone with the addition of ifosfamide and etoposide to vincristine, Adriamycin, cyclophosphamide and actinomycin: a Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) report (abstract no. 421). Proc Am Soc Clin Oncol 13:113Google Scholar
  40. 40.
    Burget EO Jr, Nesbit ME, Garnsey LA et al (1990) Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 8:1514–1524Google Scholar
  41. 41.
    Baker LH, Biermann SB (1999) NCCN practice guidelines: bone cancers. Oncology (Huntingt) 13:365–389Google Scholar
  42. 42.
    Burdach S, Jürgens H, Peters C et al (1993) Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing’s sarcoma. J Clin Oncol 11:1482–1488PubMedGoogle Scholar
  43. 43.
    Meyers PA, Krailo MD, Ladanyi M et al (2001) High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol 19:2812–2820PubMedGoogle Scholar
  44. 44.
    Huvos AG (1991) Chondrosarcoma including spindle-cell (dedifferential) and myxoid chondrosarcoma; mesenchymal chondrosarcoma. In: Huvos AG (ed) Bone tumors, 2nd edn. Saunders, Philadelphia, pp 343–381Google Scholar
  45. 45.
    Norman D, Feldman F (1972) Intra-and extra-osseous malignant histiocytoma (malignant fibrous xanthoma). Radiology 104:497–508PubMedGoogle Scholar
  46. 46.
    Bramwell VHC, Steward WP, Nooij M et al (1999) Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol 17:3260–3269PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • T. D. Peabody
  • C. W. Ryan

There are no affiliations available

Personalised recommendations